Publication | Closed Access

Insulin requirements and residual beta-cell function 12 months after concluding immunotherapy in type I diabetic patients treated with combined azathioprine and thymostimulin administration for one year

Diabetes ManagementAutoimmune DiseaseInsulin RequirementsCombined AzathioprineInsulin ManagementDiabetesImmunologyDiabetic PatientsAutoimmunityDiabetes MellitusInsulin DeliveryImmunotherapyMedicine